Cancer cells can activate diverse signaling pathways to evade the cytotoxic action of drugs.
We created and screened a library of barcoded pathway-activating mutant complementary …

Diverse pathways drive resistance to BRAF/MEK inhibitors in BRAF-mutant melanoma,
suggesting that durable control of resistance will be a challenge. By combining statistical …

Purpose: We previously reported that a fibroblast growth factor (FGF) receptor (FGFR) signaling
pathway drives growth of lung cancer cell lines of squamous and large cell histologies. …

Local adaptation directs populations towards environment-specific fitness maxima through
acquisition of positively selected traits. However, rapid environmental changes can identify …

The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical
trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI …

Our laboratory has previously shown that some gefitinib-insensitive head and neck squamous
cell carcinoma (HNSCC) cell lines exhibit dominant autocrine fibroblast growth factor …

Cancers with acquired resistance to targeted therapy can become simultaneously dependent
on the presence of the targeted therapy drug for survival, suggesting that intermittent …

A subset of lung cancers is dependent on the anaplastic lymphoma kinase (ALK) oncogene
for survival, a mechanism that is exploited by the use of the ALK inhibitor crizotinib. Despite …

Motivation: Non–small-cell lung cancer (NSCLC) is the leading cause of cancer death in the
United States. Targeted tyrosine kinase inhibitors (TKIs) directed against the epidermal …

Aerobic glycolysis or the Warburg effect (WE) is characterized by increased glucose uptake
and incomplete oxidation to lactate. Although the WE is ubiquitous, its biological role …